The bad news is there are plenty of high-efficacy vaccines already available in the United States. This includes COVID-19 vaccines from Pifzer / BioNTech and Moderna, which respectively produced vaccine efficacies of 95% and 94.1% in their large-scale U.S. studies. Even if Covaxin gains FDA approval, it may wind up collecting dust and netting Ocugen very little in sales.